Search research articles
Contact Us
Filters
Showing results (291-300 of 321) with videos related to
Page
of 33
Sort By:
Cancer Cell
|
August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC
Mei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.
Oncoimmunology
|
April 11, 2024
Redox<sup>high</sup> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma
Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Biomarker Research
|
July 23, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study
Chang Lu, Chong-Rui Xu, Yi-Chen Zhang, et al.
Journal of Extracellular Vesicles
|
October 4, 2019
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules
Jia-Tao Zhang, Hao Qin, Fiona Ka Man Cheung, et al.
Clinical Lung Cancer
|
October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets
Hai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Science Bulletin
|
January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
The New England Journal of Medicine
|
April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Molecular Oncology
|
April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy
Hai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
Page
of 33
Search research articles
Search
Showing results (291-300 of 321) with videos related to
Sort By:
Page
of 33
Cancer Cell
|
August 13, 2021
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong-Rui Xu, Ying Cheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC
Mei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.
Oncoimmunology
|
April 11, 2024
Redox<sup>high</sup> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma
Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Biomarker Research
|
July 23, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study
Chang Lu, Chong-Rui Xu, Yi-Chen Zhang, et al.
Journal of Extracellular Vesicles
|
October 4, 2019
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules
Jia-Tao Zhang, Hao Qin, Fiona Ka Man Cheung, et al.
Clinical Lung Cancer
|
October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets
Hai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Science Bulletin
|
January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
The New England Journal of Medicine
|
April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer
John V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Molecular Oncology
|
April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy
Hai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
Page
of 33